UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$438M |
| 2 |
Lockheed Martin
LMT
|
+$402M |
| 3 |
TAL Education Group
TAL
|
+$294M |
| 4 |
Microsoft
MSFT
|
+$269M |
| 5 |
Wells Fargo
WFC
|
+$235M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mastercard
MA
|
+$384M |
| 2 |
Adobe
ADBE
|
+$372M |
| 3 |
Veeva Systems
VEEV
|
+$342M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$289M |
| 5 |
Global Payments
GPN
|
+$287M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.1% |
| 2 | Consumer Discretionary | 13.57% |
| 3 | Healthcare | 12.46% |
| 4 | Financials | 11.55% |
| 5 | Communication Services | 9.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NKLA
1726
DELISTED
Nikola Corporation Common Stock
NKLA
| $1.6M | ﹤0.01% |
+3,499
| New | +$2.18M |
|
1727
Cactus
WHD
$5.7B
| $1.6M | ﹤0.01% |
61,333
| – | – |
|
1728
Axos Financial
AX
$5.63B
| $1.6M | ﹤0.01% |
42,539
| – | – |
|
1729
Tennant Co
TNC
$1.18B
| $1.59M | ﹤0.01% |
22,678
| – | – |
|
1730
Atara Biotherapeutics
ATRA
$77.6M
| $1.59M | ﹤0.01% |
3,233
+814
| +34% | +$376K |
|
1731
Renasant Corp
RNST
$3.9B
| $1.57M | ﹤0.01% |
46,756
-11,918
| -20% | -$364K |
|
1732
Unity
U
$19B
| $1.57M | ﹤0.01% |
+10,215
| New | +$1.24M |
|
|
SAND
1733
DELISTED
Sandstorm Gold
SAND
| $1.57M | ﹤0.01% |
218,788
| – | – |
|
|
EGOV
1734
DELISTED
NIC Inc
EGOV
| $1.55M | ﹤0.01% |
60,036
-9,406
| -14% | -$219K |
|
1735
Seres Therapeutics
MCRB
$50.2M
| $1.54M | ﹤0.01% |
+3,152
| New | +$1.85M |
|
1736
Aurinia Pharmaceuticals
AUPH
$2.06B
| $1.54M | ﹤0.01% |
111,959
+12,700
| +13% | +$185K |
|
1737
Cavco Industries
CVCO
$4.48B
| $1.54M | ﹤0.01% |
8,779
+1,561
| +22% | +$290K |
|
1738
US Physical Therapy
USPH
$1.24B
| $1.53M | ﹤0.01% |
12,745
| – | – |
|
|
NGD
1739
DELISTED
New Gold Inc
NGD
| $1.53M | ﹤0.01% |
694,645
+27,700
| +4% | +$56.3K |
|
|
TGI
1740
DELISTED
Triumph Group
TGI
| $1.52M | ﹤0.01% |
121,353
+49,373
| +69% | +$512K |
|
1741
The Greenbrier Companies
GBX
$1.43B
| $1.52M | ﹤0.01% |
41,876
+6,300
| +18% | +$208K |
|
1742
Myriad Genetics
MYGN
$311M
| $1.52M | ﹤0.01% |
76,950
-2,884
| -4% | -$46.6K |
|
1743
Equinor
EQNR
$97.4B
| $1.52M | ﹤0.01% |
92,339
| – | – |
|
1744
FB Financial Corp
FBK
$3.04B
| $1.52M | ﹤0.01% |
43,639
| – | – |
|
|
DCH
1745
Dauch Corp
DCH
$1.58B
| $1.51M | ﹤0.01% |
181,596
+18,142
| +11% | +$137K |
|
1746
Apogee Enterprises
APOG
$887M
| $1.51M | ﹤0.01% |
47,539
| – | – |
|
1747
Verra Mobility
VRRM
$720M
| $1.5M | ﹤0.01% |
111,995
-849
| -0.8% | -$9.99K |
|
1748
Workhorse Group
WKHS
$34.5M
| $1.5M | ﹤0.01% |
+25
| New | +$1.63M |
|
|
SRNE
1749
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $1.5M | ﹤0.01% |
220,016
+98,990
| +82% | +$795K |
|
1750
TriMas Corp
TRS
$1.43B
| $1.5M | ﹤0.01% |
47,236
+2,078
| +5% | +$56.9K |
|
Similar funds
UBS AM's Q4 2020 Portfolio in Review
As of Q4 2020, UBS AM held 2,632 positions worth $213B, up 15% from $186B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
UBS AM's Q4 2020 filing shows 139 new, 1,393 increased, 625 reduced and 83 closed positions. Its largest new stake was Maravai LifeSciences: 3,763,012 shares worth $106M. The largest sale was Mastercard, an estimated $384M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- UBS AM's largest Q4 2020 buy was Maravai LifeSciences: 3,763,012 shares worth $106M.
- UBS AM added most to Apple in Q4 2020, an estimated $438M increase.
- UBS AM's biggest Q4 2020 reduction was Mastercard, cutting an estimated $384M.
- UBS AM fully exited State Street Technology Select Sector SPDR ETF in Q4 2020, selling an estimated $115M.
- UBS AM's ten largest holdings make up 23% of its $213B portfolio in Q4 2020.
- UBS AM opened 139 new positions and closed 83 in Q4 2020.
- UBS AM's portfolio value rose 15% quarter-over-quarter to $213B.
Based on UBS AM's 13F filing for Q4 2020, filed 17 Feb 2021.